Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).
about
Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7The emerging role of the LIV-1 subfamily of zinc transporters in breast cancerUnderstanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models.NSP-CAS Protein Complexes: Emerging Signaling Modules in CancerAssociation of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistanceBreast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane rufflingAdaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells.Pathways to tamoxifen resistance.ER-α36: a novel biomarker and potential therapeutic target in breast cancer.Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.Cancer stem cells and side population cells in breast cancer and metastasis.MicroRNA-mediated drug resistance in breast cancer.Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.The molecular landscape of premenopausal breast cancer.Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancerApplication of DNA microarray technology in determining breast cancer prognosis and therapeutic response.Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.Establishment of animal model for the analysis of cancer cell metastasis during radiotherapyHeregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.Evaluation of the current knowledge limitations in breast cancer research: a gap analysisHormone response in ovarian cancer: time to reconsider as a clinical target?Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.Expression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3-kinase/Akt survival pathway in tamoxifen resistant breast cancer cells.Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice.Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells.Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.The dual kinase complex FAK-Src as a promising therapeutic target in cancerBreast cancer stem cells and their role in resistance to endocrine therapy.Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance.Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies.The exposure of breast cancer cells to fulvestrant and tamoxifen modulates cell migration differently.(-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.Role of the CYP3A4-mediated 11,12-epoxyeicosatrienoic acid pathway in the development of tamoxifen-resistant breast cancer
P2860
Q24304911-8F868025-8800-4F24-B469-72BC48141111Q24682854-E9DFBE4C-EB4D-4A9E-8C47-EED52B87E41BQ24813647-A27E4F32-1AD2-4142-BE58-4336FCB1F261Q28281166-6142D596-E284-4E6E-8610-82FDD18B7D7AQ28308160-162225C0-BA5D-497F-8960-F4DB4ADD8A2DQ30411760-1D4F5EC9-BBB6-4818-A782-1428D56A874BQ30440238-1380657F-3628-4595-870E-742DC3A5B8C0Q30441001-C08BB36B-C763-4B02-9F3A-BC000CAC7106Q34140162-F63B94F1-12A8-494B-B2AC-4A934E63CC17Q34435089-AEA25C6B-1C00-425D-94E0-D1497C2A6F46Q34857146-77BEE4A9-D768-4D64-82E8-87B27AA24F43Q35038054-77BC60E7-58B8-464D-97CD-04AD886D1149Q35165126-DFF658C7-FD84-40A7-8770-412A51014DD7Q35569694-6ECD70DE-9CDA-409C-9AEA-FCB329B43A00Q35683561-1F458BF4-605E-4330-8E6B-5ED106F8F28FQ35937970-B700141E-5896-4560-BA0C-DCC328F00F3FQ36172210-33B2CABB-16D1-4C72-A364-B6F4372DCEE4Q36210870-976F1B26-4DF8-4134-AA73-313AB77818BEQ36245528-6C391697-DA5B-44CD-A762-7D64545E54C6Q36384068-CBCFD27B-1BBC-4197-9B5F-6F39789B1A65Q36393289-7A4ED218-7B6A-4A59-BE38-C04D2F6B5AC4Q36653598-BEEA7E6A-D9FB-43D7-B05D-22824DDBC65CQ36678664-6CAC3C91-ED11-4140-B535-E290D7ACE17DQ36966197-E0034E9D-F69D-4AA7-989A-C60069A08F70Q37134040-1798D55B-E7D9-46F6-B2AE-EF683861565FQ37345203-9C16244A-F8C8-45C7-A560-ED4C5ADA721AQ37354803-7A8997CA-7F24-4F17-8A27-DC4595E09911Q37362627-FDC7E707-D5AA-4D02-B100-A0E93CE4163BQ37422870-501E8208-5503-476C-87CA-207A5E58D4C8Q37690245-A1D5F4DC-8A3D-4C7B-943F-FE290E16EFFFQ37771259-A60522D7-C2FD-464F-817F-4BA13B162682Q37901429-6E757579-2C03-423A-AF86-955545A6CC8EQ38845190-8D0596A0-53E7-47EC-AC97-B383F6CCE2EFQ38946429-99EB8CAC-501A-4E96-BE8E-C5B192374138Q39111584-F7E463C6-8C25-4656-B995-8CE75129B456Q39707051-EC0CECD4-6320-4F52-A14B-165F05B962E3Q39720714-96FC182C-4365-473B-BC28-DEF5FCC2ABD5Q40262820-9CD639C6-B2DC-4EE0-A0B1-6225C3F78EF2Q41134570-629671C5-16EE-4EE2-A698-CA3DAA896E57Q42378504-AF9BF888-F615-4A32-9FF8-9B673F54A440
P2860
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Tamoxifen resistance in breast ...... gefitinib ('Iressa', ZD1839).
@en
type
label
Tamoxifen resistance in breast ...... gefitinib ('Iressa', ZD1839).
@en
prefLabel
Tamoxifen resistance in breast ...... gefitinib ('Iressa', ZD1839).
@en
P2093
P1476
Tamoxifen resistance in breast ...... y gefitinib ('Iressa', ZD1839)
@en
P2093
Alan Wakeling
Carol Dutkowskil
Denise Barrow
Robert I Nicholson
P304
P356
10.1023/B:CLIN.0000037697.76011.1D
P577
2004-01-01T00:00:00Z
P6179
1034162687